

William B Parker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11484726/publications.pdf>

Version: 2024-02-01

44
papers

2,430
citations

331670

21
h-index

265206

42
g-index

45
all docs

45
docs citations

45
times ranked

2484
citing authors

#	ARTICLE	IF	CITATIONS
1	The use of <i>Trichomonas vaginalis</i> purine nucleoside phosphorylase to activate fludarabine in the treatment of solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2020, 85, 573-583.	2.3	5
2	Intratumoral generation of 2- β -fluoroadenine to treat solid malignancies of the head and neck. <i>Head and Neck</i> , 2019, 41, 1979-1983.	2.0	7
3	Use of <i>E. coli</i> Purine Nucleoside Phosphorylase in the Treatment of Solid Tumors. <i>Current Pharmaceutical Design</i> , 2018, 23, 7003-7024.	1.9	6
4	Clofarabine: Structure, Mechanism of Action, and Clinical Pharmacology. , 2017, , 261-286.		2
5	6-Methylpurine derived sugar modified nucleosides: Synthesis and in vivo antitumor activity in D54 tumor expressing M64V- <i>Escherichia coli</i> purine nucleoside phosphorylase. <i>European Journal of Medicinal Chemistry</i> , 2016, 108, 616-622.	5.5	5
6	6-Methylpurine derived sugar modified nucleosides: Synthesis and evaluation of their substrate activity with purine nucleoside phosphorylases. <i>Bioorganic Chemistry</i> , 2016, 65, 9-16.	4.1	8
7	PRE-CLINICAL AND CLINICAL VALIDATION OF AN ANTI-CANCER MODALITY THAT ABLATES REFRACTORY, LOW GROWTH FRACTION TUMORS. <i>Transactions of the American Clinical and Climatological Association</i> , 2016, 127, 59-70.	0.5	2
8	In vivo antitumor activity of intratumoral fludarabine phosphate in refractory tumors expressing <i>E. coli</i> purine nucleoside phosphorylase. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 321-329.	2.3	27
9	Synthesis and evaluation of the substrate activity of C-6 substituted purine ribosides with <i>E. coli</i> purine nucleoside phosphorylase: Palladium mediated cross-coupling of organozinc halides with 6-chloropurine nucleosides. <i>European Journal of Medicinal Chemistry</i> , 2012, 47, 167-174.	5.5	27
10	The Crystal Structure of <i>Streptococcus pyogenes</i> Uridine Phosphorylase Reveals a Distinct Subfamily of Nucleoside Phosphorylases. <i>Biochemistry</i> , 2011, 50, 6549-6558.	2.5	12
11	Structure of grouper iridovirus purine nucleoside phosphorylase. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2010, 66, 155-162.	2.5	4
12	Synthesis and anti-Hantaan virus activity of N1-3-fluorophenyl-inosine. <i>Antiviral Research</i> , 2009, 83, 80-85.	4.1	10
13	Enzymology of Purine and Pyrimidine Antimetabolites Used in the Treatment of Cancer. <i>Chemical Reviews</i> , 2009, 109, 2880-2893.	47.7	484
14	Regioselective Metalation of 6-Methylpurines: Synthesis of Fluoromethyl Purines and Related Nucleosides for Suicide Gene Therapy of Cancer. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2009, 28, 642-656.	1.1	4
15	An Immunocompetent Murine Model for Oncolysis with an Armed and Targeted Measles Virus. <i>Molecular Therapy</i> , 2007, 15, 1991-1997.	8.2	79
16	Lymphoma Chemovirotherapy: CD20-Targeted and Convertase-Armed Measles Virus Can Synergize with Fludarabine. <i>Cancer Research</i> , 2007, 67, 10939-10947.	0.9	86
17	Activity of Ribavirin against Hantaan Virus Correlates with Production of Ribavirin-5'-Triphosphate, Not with Inhibition of IMP Dehydrogenase. <i>Antimicrobial Agents and Chemotherapy</i> , 2007, 51, 84-88.	3.2	45
18	Long intracellular retention of 4-thio-arabinofuranosylcytosine 5'-triphosphate as a critical factor for the anti-solid tumor activity of 4-thio-arabinofuranosylcytosine. <i>Cancer Chemotherapy and Pharmacology</i> , 2006, 57, 772-780.	2.3	12

#	ARTICLE	IF	CITATIONS
19	PNP Anticancer Gene Therapy. <i>Current Topics in Medicinal Chemistry</i> , 2005, 5, 1259-1274.	2.1	32
20	Antibiotic-Mediated Chemoprotection Enhances Adaptation of <i>E. coli</i> PNP for Herpes Simplex Virus-Based Glioma Therapy. <i>Human Gene Therapy</i> , 2005, 16, 339-347.	2.7	23
21	Metabolism and antiviral activity of ribavirin. <i>Virus Research</i> , 2005, 107, 165-171.	2.2	197
22	DESIGN AND EVALUATION OF 5'-MODIFIED NUCLEOSIDE ANALOGS AS PRODRUGS FOR AN <i>E. COLI</i> PURINE NUCLEOSIDE PHOSPHORYLASE MUTANT. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2005, 24, 387-392.	1.1	13
23	Excellent In vivo Bystander Activity of Fludarabine Phosphate against Human Glioma Xenografts that Express the <i>Escherichia coli</i> Purine Nucleoside Phosphorylase Gene. <i>Cancer Research</i> , 2004, 64, 6610-6615.	0.9	54
24	Metabolism of 2-methyladenosine in <i>Mycobacterium tuberculosis</i> . <i>Tuberculosis</i> , 2004, 84, 327-336.	1.9	14
25	Designer Gene Therapy Using an <i>Escherichia coli</i> Purine Nucleoside Phosphorylase/Prodrug System. <i>Chemistry and Biology</i> , 2003, 10, 1173-1181.	6.0	43
26	Antitumor activity of 2-fluoro-2'-deoxyadenosine against tumors that express <i>Escherichia coli</i> purine nucleoside phosphorylase. <i>Cancer Gene Therapy</i> , 2003, 10, 23-29.	4.6	74
27	A Long-Acting Suicide Gene Toxin, 6-Methylpurine, Inhibits Slow Growing Tumors after a Single Administration. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 304, 1280-1284.	2.5	34
28	Structural Basis for Substrate Specificity of <i>Escherichia coli</i> Purine Nucleoside Phosphorylase. <i>Journal of Biological Chemistry</i> , 2003, 278, 47110-47118.	3.4	76
29	Phosphorylation of 4'-thio- β -D-Arabinofuranosylcytosine and Its Analogs by Human Deoxycytidine Kinase. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2003, 304, 1314-1322.	2.5	21
30	The metabolism of 2-methyladenosine in <i>Mycobacterium smegmatis</i> . <i>Microbiology (United Kingdom)</i> , 2002, 148, 289-295.	1.8	16
31	Metabolism of 4'-thio- β -D-arabinofuranosylcytosine in CEM cells. <i>Biochemical Pharmacology</i> , 2000, 60, 1925-1932.	4.4	35
32	Metabolism of O ⁶ -Propyl and N ⁶ -Propyl-carbovir in CEM Cells. <i>Nucleosides, Nucleotides and Nucleic Acids</i> , 2000, 19, 795-804.	1.1	4
33	Gene Therapy of Cancer: Activation of Nucleoside Prodrugs with <i>E. coli</i> Purine Nucleoside Phosphorylase. <i>Nucleosides & Nucleotides</i> , 1999, 18, 745-757.	0.5	42
34	Metabolism and Metabolic Actions of 6-Methylpurine and 2-Fluoroadenine in Human Cells. <i>Biochemical Pharmacology</i> , 1998, 55, 1673-1681.	4.4	103
35	Cell to Cell Contact Is Not Required for Bystander Cell Killing by <i>Escherichia coli</i> Purine Nucleoside Phosphorylase. <i>Journal of Biological Chemistry</i> , 1998, 273, 2322-2328.	3.4	59
36	<i>In Vivo</i> Gene Therapy of Cancer with <i>E. coli</i> Purine Nucleoside Phosphorylase. <i>Human Gene Therapy</i> , 1997, 8, 1637-1644.	2.7	110

#	ARTICLE	IF	CITATIONS
37	Lack of mitochondrial toxicity in CEM cells treated with carbovir. <i>Antiviral Research</i> , 1997, 34, 131-136.	4.1	18
38	6-Substituted Derivatives of Carbovir: Anti-HIV Activity. <i>Nucleosides & Nucleotides</i> , 1995, 14, 1703-1708.	0.5	8
39	Lack of synergy in the inhibition of HIV-1 reverse transcriptase by combinations of the 5'-triphosphates of various anti-HIV nucleoside analogs. <i>Antiviral Research</i> , 1993, 22, 295-308.	4.1	30
40	Interference with HIV-1 reverse transcriptase-catalyzed DNA chain elongation by the 5'-triphosphate of the carbocyclic analog of 2'-deoxyguanosine. <i>Antiviral Research</i> , 1992, 19, 325-332.	4.1	5
41	Metabolism and mechanism of action of 5-fluorouracil. , 1990, 48, 381-395.		373
42	Comparison of the effect of Carbovir, AZT, and dideoxynucleoside triphosphates on the activity of human immunodeficiency virus reverse transcriptase and selected human polymerases. <i>Biochemical and Biophysical Research Communications</i> , 1989, 161, 393-398.	2.1	105
43	Characterization of a novel inhibitor of human DNA polymerases: 3,4,5-tri-O-galloylquinic acid. <i>Biochemical Pharmacology</i> , 1989, 38, 3759-3765.	4.4	18
44	Anti-Aids Agents, 1. Isolation and Characterization of Four New Tetragalloylquinic Acids as a New Class of HIV Reverse Transcriptase Inhibitors from Tannic Acid. <i>Journal of Natural Products</i> , 1989, 52, 762-768.	3.0	98